New Pharmacotherapeutic Approaches for Chronic Obstructive Pulmonary Disease

Peter Calverley; Ben Vlies

doi:10.1055/s-0035-1556057

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2015; 36(04): 523-542
DOI: 10.1055/s-0035-1556057

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

New Pharmacotherapeutic Approaches for Chronic Obstructive Pulmonary Disease

Peter Calverley

¹School of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom

,

Ben Vlies

¹School of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom

› Author Affiliations

Abstract

The last 5 years have seen a proliferation of data about the best way to treat chronic obstructive pulmonary disease (COPD). New long-acting inhaled β-agonist and antimuscarinic drugs have been developed as a once-daily inhaled corticosteroid. Studies have tested whether these agents are safe and effective alone or in combination. Alternative strategies to treatment including phosphodiesterase-4 inhibition and long-term antibiotic treatment have become reasonable alternatives to more established approaches, at least in terms of preventing COPD exacerbations. New data are beginning to define which patients benefit from which treatments and this will help us develop more appropriate treatment regimes. These topics are considered in this review which provides an overview of the latest data and some direction as to how these findings can be applied in practice.

Keywords

bronchodilator - long-acting β-agonist - long-acting antimuscarinic - inhaled corticosteroids - combination therapy - phosphodiesterase-4 inhibition - long-term antibiotics

Full Text

References

References
1 Jones PW. The COPD Assessment Test: what have we learned over its first 5 years?. Eur Respir J 2014; 44 (4) 833-834
2 Vestbo J, Hurd SS, Agustí AG , et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187 (4) 347-365
3 Donaldson GC, Müllerova H, Locantore N , et al. Factors associated with change in exacerbation frequency in COPD. Respir Res 2013; 14: 79
4 Agusti A, Edwards LD, Celli B , et al; ECLIPSE Investigators. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013; 42 (3) 636-646
5 Moore RP, Berlowitz DJ, Denehy L , et al. A randomised trial of domiciliary, ambulatory oxygen in patients with COPD and dyspnoea but without resting hypoxaemia. Thorax 2011; 66 (1) 32-37
6 Sciurba FC, Ernst A, Herth FJ , et al; VENT Study Research Group. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010; 363 (13) 1233-1244
7 Leuppi JD, Schuetz P, Bingisser R , et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309 (21) 2223-2231
8 Müllerova H, Chigbo C, Hagan GW , et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012; 106 (8) 1124-1133
9 Celli BR, Thomas NE, Anderson JA , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178 (4) 332-338
10 Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP ; UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180 (10) 948-955
11 Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP, Wise RA. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185 (12) 1301-1306
12 Bateman ED, Tashkin D, Siafakas N , et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med 2010; 104 (10) 1460-1472
13 Bateman E, Singh D, Smith D , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010; 5: 197-208
14 Beasley R, Singh S, Loke YK, Enright P, Furberg CD. Call for worldwide withdrawal of tiotropium Respimat mist inhaler. BMJ 2012; 345: e7390
15 Jenkins CR, Beasley R. Tiotropium Respimat increases the risk of mortality. Thorax 2013; 68 (1) 5-7
16 Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG, Sturkenboom MC. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J 2013; 42 (3) 606-615
17 Wise RA, Anzueto A, Calverley P , et al. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res 2013; 14: 40
18 Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 2006; 61 (10) 854-862
19 Vogelmeier C, Hederer B, Glaab T , et al; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364 (12) 1093-1103
20 Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther 2011; 33 (12) 1974-1984
21 Feldman G, Siler T, Prasad N , et al; INLIGHT 1 study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11
22 Kinoshita M, Lee SH, Hang LW , et al; Indacaterol Asian COPD Study Investigators. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology 2012; 17 (2) 379-389
23 Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B ; INDORSE Study Investigators. Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011; 140 (1) 68-75
24 O'Donnell DE, Casaburi R, Vincken W , et al; INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011; 105 (7) 1030-1036
25 Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C ; INSIST study group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011; 105 (5) 719-726
26 Kornmann O, Dahl R, Centanni S , et al; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37 (2) 273-279
27 Dahl R, Chung KF, Buhl R , et al; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65 (6) 473-479
28 Buhl R, Dunn LJ, Disdier C , et al; INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011; 38 (4) 797-803
29 Donohue JF, Fogarty C, Lötvall J , et al; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182 (2) 155-162
30 Decramer ML, Chapman KR, Dahl R , et al; INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1 (7) 524-533
31 Hanania NA, Feldman G, Zachgo W , et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012; 142 (1) 119-127
32 Maltais F, Singh S, Donald AC , et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis 2014; 8 (6) 169-181
33 Kerwin EM, Scott-Wilson C, Sanford L , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med 2013; 107 (4) 560-569
34 Martinez FJ, Boscia J, Feldman G , et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med 2013; 107 (4) 550-559
35 Celli B, Crater G, Kilbride S , et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014;
36 Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013; 107 (10) 1538-1546
37 Ferguson GT, Feldman GJ, Hofbauer P , et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9: 629-645
38 Feldman GJ, Bernstein JA, Hamilton A, Nivens MC, Korducki L, LaForce C. The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies. Springerplus 2014; 3: 419
39 Koch A, Pizzichini E, Hamilton A , et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9: 697-714
40 Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012; 7: 503-513
41 D'Urzo A, Kerwin E, Overend T, D'Andrea P, Chen H, Goyal P. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin 2014; 30 (3) 493-508
42 Chapman KR, Beeh KM, Beier J , et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 2014; 14: 4
43 Decramer M, Maltais F, Feldman G , et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013; 185 (2) 393-399
44 Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014; 43 (1) 72-81 [corrected in Eur Respir J 2014;44(2):555]
45 Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014; 15: 78
46 Maltais F, Celli B, Casaburi R , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011; 105 (4) 580-587
47 Jones PW, Rennard SI, Agusti A , et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011; 12: 55
48 Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF ; ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9 (2) 90-101
49 Rennard SI, Scanlon PD, Ferguson GT , et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig 2013; 33 (12) 893-904
50 Jones PW, Singh D, Bateman ED , et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012; 40 (4) 830-836
51 Chanez P, Burge PS, Dahl R , et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther 2010; 23 (1) 15-21
52 Beier J, Kirsten AM, Mróz R , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD 2013; 10 (4) 511-522
53 Wedzicha JA, Decramer M, Ficker JH , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1 (3) 199-209
54 Lötvall J, Bakke PS, Bjermer L , et al. Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open 2012; 2 (1) e000370
55 Dransfield MT, Feldman G, Korenblat P , et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med 2014; 108 (8) 1171-1179
56 Agustí A, de Teresa L, De Backer W , et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J 2014; 43 (3) 763-772
57 Dransfield MT, Bourbeau J, Jones PW , et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1 (3) 210-223
58 Calverley PM, Anderson JA, Celli B , et al; TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010; 65 (8) 719-725
59 COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105 (5) 1411-1419
60 Mahler DA, D'Urzo A, Bateman ED , et al; INTRUST-1 and INTRUST-2 study investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012; 67 (9) 781-788
61 ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis 2014; 9: 1133-1144
62 Dahl R, Chapman KR, Rudolf M , et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013; 107 (10) 1558-1567
63 Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014; 9: 215-228
64 Mahler DA, Decramer M, D'Urzo A , et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014; 43 (6) 1599-1609
65 Vogelmeier CF, Bateman ED, Pallante J , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013; 1 (1) 51-60
66 Bateman ED, Ferguson GT, Barnes N , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42 (6) 1484-1494
67 Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med 2014; 108 (12) 1752-1760
68 Decramer M, Anzueto A, Kerwin E , et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014; 2 (6) 472-486
69 Decramer M, Rutten-van Mölken M, Dekhuijzen PN , et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365 (9470) 1552-1560
70 Zheng JP, Kang J, Huang SG , et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371 (9629) 2013-2018
71 Zheng JP, Wen FQ, Bai CX , et al; PANTHEON study group. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014; 2 (3) 187-194
72 Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176 (2) 154-161
73 Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D, Bethke TD. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366 (9485) 563-571
74 O'Donnell DE, Bredenbröker D, Brose M, Webb KA. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J 2012; 39 (5) 1104-1112
75 Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast—the importance of defining different subsets of patients with COPD. Respir Res 2011; 12: 18
76 Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374 (9691) 685-694
77 Fabbri LM, Calverley PM, Izquierdo-Alonso JL , et al; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009; 374 (9691) 695-703
78 Bateman ED, Rabe KF, Calverley PM , et al. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur Respir J 2011; 38 (3) 553-560
79 Wedzicha JA, Rabe KF, Martinez FJ , et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 2013; 143 (5) 1302-1311
80 White WB, Cooke GE, Kowey PR , et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 2013; 144 (3) 758-765
81 Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015; 385 (9971) 857-866
82 Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med 2014; 35 (1) 157-163
83 Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347 (7) 465-471
84 Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014; 384 (9944) 691-702
85 Sethi S, Jones PW, Theron MS , et al; PULSE Study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11: 10
86 Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178 (11) 1139-1147
87 Albert RK, Connett J, Bailey WC , et al; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365 (8) 689-698
88 Han MK, Tayob N, Murray S , et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014; 189 (12) 1503-1508
89 Uzun S, Djamin RS, Kluytmans JA , et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014; 2 (5) 361-368
90 Albert P, Calverley PM. Drugs (including oxygen) in severe COPD. Eur Respir J 2008; 31 (5) 1114-1124
91 Criner GJ, Connett JE, Aaron SD , et al; COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370 (23) 2201-2210
92 MacNee W, Allan RJ, Jones I, De Salvo MC, Tan LF. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 2013; 68 (8) 738-745
93 Watz H, Barnacle H, Hartley BF, Chan R. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014; 2 (1) 63-72
94 Brightling CE, Bleecker ER, Panettieri Jr RA , et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014; 2 (11) 891-901
95 Ferguson GT, Calverley PM, Anderson JA , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009; 136 (6) 1456-1465
96 Crim C, Calverley PM, Anderson JA , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34 (3) 641-647
97 Calverley PM, Stockley RA, Seemungal TA , et al; Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139 (3) 505-512
98 Crim C, Dransfield MT, Bourbeau J , et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015; 12 (1) 27-34
99 Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176 (2) 162-166
100 Sin DD, Tashkin D, Zhang X , et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374 (9691) 712-719
101 Albert RK, Schuller JL ; COPD Clinical Research Network. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014; 189 (10) 1173-1180
102 Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013; 1 (3) 262-274
103 O'Reilly J, Jones MM, Parnham J, Lovibond K, Rudolf M ; Guideline Development Group. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010; 340: c3134
104 Magnussen H, Watz H, Kirsten A , et al. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir Med 2014; 108 (4) 593-599
105 Jarad NA, Wedzicha JA, Burge PS, Calverley PM ; ISOLDE Study Group. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999; 93 (3) 161-166
106 Wouters EF, Postma DS, Fokkens B , et al; COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60 (6) 480-487
107 Magnussen H, Disse B, Rodriguez-Roisin R , et al; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371 (14) 1285-1294
108 Rabe KF, Fabbri LM, Israel E , et al. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med 2014; 2 (1) 44-53
109 Bafadhel M, McKenna S, Terry S , et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186 (1) 48-55
110 Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 2014; 44 (3) 789-791
111 Albert P, Agusti A, Edwards L , et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012; 67 (8) 701-708
112 Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med 2013; 1 (7) 564-573
113 Gershon AS, Campitelli MA, Croxford R , et al. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014; 312 (11) 1114-1121
114 Vestbo J, Anderson J, Brook RD , et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013; 41 (5) 1017-1022